Cebreo Medical announced that its NeuroBuds device has received CE marking, confirming conformity with applicable EU requirements.
Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment.
Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit compliance in long-term EEG monitoring. Because it is comfortable and simple enough for unassisted use, it supports monitoring periods of up to three months, with repeat measurements.
With CE marking secured, Cebreo Medical will expand commercial availability across European research and clinical sites while advancing its U.S. regulatory pathway.
